Beyond biologics: Amgen bets new drugs will pay dividend
Amgen executives believe the biotech giant will grow substantially in the next decade, pursuing drugs that treat major melanoma and bone loss.
ValueClick defies its skeptics
ValueClick is out to prove to investors that it still has some pluck after more than a decade in the digital marketing business.
Bank earnings rebound signals better times
Santa Barbara Bank & Trust and its smaller banking peers in the region are reporting improved earnings.
Teledyne regroups in face of defense cuts
Thousand Oaks-based Teledyne Technologies, a $1.6 billion military-industrial conglomerate, is rearranging itself to bolster its commercial camera sensor lines and shift toward the defense spending that’s farthest from the chopping block.
Teledyne sells small-aircraft engine division for $186M
Teledyne is selling its small-aircraft engine business for $186 million to a Chinese company.
Semtech to pay $20M to settle options suit
Semtech Corp. said Dec. 8 that it will pay $20 million in cash to settle a class action securities lawsuit.
